Hexagon Nutrition Ltd
Incorporated in 1993, Hexagon Nutrition
Ltd is a research-driven nutrition company.[1]
- Market Cap ₹ 855 Cr.
- Current Price ₹ 69.5
- High / Low ₹ 78.7 / 48.0
- Stock P/E 22.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE 16.4 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 52.1% CAGR over last 5 years
Cons
- Earnings include an other income of Rs.15.6 Cr.
- Working capital days have increased from 102 days to 204 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Packaged Foods
Part of Nifty IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 99 | 86 | 107 | 114 | 132 | 319 | |
| 88 | 79 | 94 | 115 | 119 | 276 | |
| Operating Profit | 10 | 7 | 13 | -1 | 13 | 43 |
| OPM % | 11% | 9% | 12% | -1% | 10% | 14% |
| 1 | 3 | 2 | 2 | 5 | 16 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 3 | 2 | 2 | 3 | 3 | 6 |
| Profit before tax | 8 | 7 | 13 | -3 | 14 | 51 |
| Tax % | 7% | 24% | 29% | 18% | 25% | 26% |
| 7 | 6 | 9 | -3 | 10 | 38 | |
| EPS in Rs | 0.67 | 0.51 | 0.81 | -0.28 | 0.95 | 3.45 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 41% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 52% |
| 3 Years: | 273% |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 35 | 37 | 56 | 51 | 61 | 220 |
| 26 | 25 | 22 | 28 | 40 | 25 | |
| 24 | 21 | 26 | 36 | 28 | 49 | |
| Total Liabilities | 96 | 94 | 116 | 126 | 141 | 305 |
| 21 | 20 | 20 | 22 | 25 | 41 | |
| CWIP | 0 | 0 | 2 | 1 | 2 | 1 |
| Investments | 12 | 16 | 20 | 16 | 8 | 34 |
| 62 | 58 | 74 | 86 | 107 | 230 | |
| Total Assets | 96 | 94 | 116 | 126 | 141 | 305 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 10 | 5 | 1 | 7 | -2 | 8 | |
| -1 | -2 | -11 | -8 | -8 | -19 | |
| -5 | -4 | 7 | 3 | 11 | 11 | |
| Net Cash Flow | 5 | -1 | -3 | 2 | 1 | -1 |
| Free Cash Flow | 9 | 5 | -4 | 2 | -8 | 2 |
| CFO/OP | 113% | 75% | 31% | -852% | 5% | 44% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 50 | 57 | 52 | 76 | 67 | 89 |
| Inventory Days | 128 | 149 | 192 | 150 | 146 | 145 |
| Days Payable | 108 | 95 | 108 | 152 | 80 | 61 |
| Cash Conversion Cycle | 71 | 110 | 136 | 74 | 132 | 173 |
| Working Capital Days | 89 | 58 | 76 | 65 | 1 | 204 |
| ROCE % | 10% | 15% | 2% | 15% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Branded Nutrition Segment Revenue Share % of revenue |
|
||
| Capacity Utilization - Clinical Nutrition % |
|||
| Export Revenue Share (Rest of World) % of revenue |
|||
| Number of Distributors count |
|||
| Number of Permanent Employees (Consolidated) count |
|||
| Production Volume - Dry Pre-mix MT |
|||
| Production Volume - Ready-to-Use Food (RUF/RUTF) MT |
|||
| Top 10 Customer Revenue Concentration % of revenue |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Audio recording of 17 July 2026 earnings call for audited FY2026 results is now available.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Clarification Regarding Disclosure Contained In The Red Herring Prospectus/ Prospectus
2d - Hexagon Nutrition clarified and corrected RHP/prospectus disclosures; no impact on issue objects, financials, operations, or shareholders.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Disclosure under regulation 30 of SEBI Regulations, 2015 - Q4FY26 result presentation
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 Jul - Hexagon Nutrition schedules FY26 earnings conference call on 17 July 2026 at 4:00 p.m. IST.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 Jul - Pursuant to the provisions of Regulation 30 of the Listing Regulations read with Para A (15)(a) of Part A of Schedule III thereto, this is …
Business Profile:[1]
Hexagon Nutrition is a research-
driven nutrition company engaged
in the development, manufacturing
and marketing of nutrition products
across micronutrient premixes, branded
wellness and clinical nutrition, therapeutic formulations, ready-to-use foods (RUFs)
and micronutrient powders (MNPs).